Clinical Trials Directory

Trials / Completed

CompletedNCT05857878

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1815368 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
59 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This trial aims to investigate safety, tolerability, and pharmacokinetics following multiple rising doses of BI 1815368 in healthy male subjects.

Conditions

Interventions

TypeNameDescription
DRUGBI 1815368BI 1815368
DRUGMatching placeboMatching placebo

Timeline

Start date
2023-06-23
Primary completion
2024-06-06
Completion
2024-06-06
First posted
2023-05-15
Last updated
2024-11-19

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT05857878. Inclusion in this directory is not an endorsement.

A Study to Test How Well Different Doses of BI 1815368 Are Tolerated by Healthy Men (NCT05857878) · Clinical Trials Directory